Early Phase 1 Malignancies Clinical Trials
9 recruitingEarly Phase 1
What is a Early Phase 1 trial?
Early Phase 1 trials are the earliest stage of testing in humans. These small studies focus on how a drug is processed in the body and how it affects the body, often enrolling just a handful of participants to establish initial safety data.
Showing 1–9 of 9 trials
Recruiting
Early Phase 1
A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.
PineoblastomaMedulloblastoma RecurrentEpendymoma Recurrent+3 more
Children's National Research Institute18 enrolled1 locationNCT07017816
Recruiting
Early Phase 1
A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer
Solid Malignancies
Immunome, Inc.105 enrolled1 locationNCT07505771
Recruiting
Early Phase 1
Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies
B-cell Malignancies
Xinqiao Hospital of Chongqing47 enrolled1 locationNCT07349849
Recruiting
Early Phase 1
Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies
Hematolymphoid Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd.15 enrolled1 locationNCT07338604
Recruiting
Early Phase 1
Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies
Relapsed/Refractory B-cell Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology6 enrolled1 locationNCT07240974
Recruiting
Early Phase 1
UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.
CD19-positive Relapsed or Refractory B-cell Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd.10 enrolled1 locationNCT06092047
Recruiting
Early Phase 1
Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors
Pleural Effusion, MalignantPeritoneal Carcinoma MetastaticHER2 Positive Malignancies
Sichuan University18 enrolled1 locationNCT04684459
Recruiting
Early Phase 1
APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
Hematologic Malignancies
Ascentage Pharma Group Inc.90 enrolled5 locationsNCT03537482
Recruiting
Early Phase 1
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies
Lymphoid Hematological MalignanciesRelapsed and Refractory
He Huang100 enrolled1 locationNCT04283006